Literature DB >> 15868361

Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

M Fassbach1, B Schwartzkopff.   

Abstract

OBJECTIVES: The hypothesis of impaired collagenolysis in patients with hypertrophic cardiomyopathy (HCM) was tested by measuring serum markers of type-I collagen metabolism. These markers were correlated with echocardiographic parameters of diastolic function.
BACKGROUND: HCM is a common disease in the adult population with a wide range of clinical manifestations. Left ventricular hypertrophy and increased intramyocardial collagen content are known to cause diastolic dysfunction in patients with HCM.
METHODS: In 26 patients with HCM and 38 control subjects (aged: 57+/-3 and 54+/-2 years, p=n.s.) serum levels of collagenolytic matrixmetalloproteinase-1 (MMP-1) and its inhibitor TIMP-1, the markers for collagen type-I synthesis (PICP) and degradation (ICTP) were determined by ELISA and RIA. Diastolic function were determined by Doppler echocardiography.
RESULTS: Free TIMP-1 was elevated in HCM compared to controls (216,78+/-9,89 vs 183.77+/-7.57 ng/ml ; p=0.006) as well as PICP (165.92+/-10.26 vs 114.57+/-6.38 mug/l; p<0.001). Free MMP-1 was significantly lower in HCM (1.13+/-0.20 vs 2.33+/-0.34; p=0.01). ICTP did not differ. The MMP-1/TIMP-1 ratio was significantly lower in HCM (0.006+/-0.001 vs 0.012+/-0.001, p=0.003). PICP correlated positively with diastolic E/A ratio (r=0.389; p=0.05) and septal thickness (r=0.484; p=0.01).
CONCLUSIONS: Serum marker of collagen synthesis (PICP) is increased in patients with HCM. Increased marker for inhibition of collagenolysis (TIMP-1) and a disturbed balance of collagen synthesis and degradation (ratio) with a predominance of inhibition of collagenolysis indicates collagen accumulation (fibrosis), which explains passive diastolic dysfunction in patients with HCM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868361     DOI: 10.1007/s00392-005-0214-5

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  35 in total

Review 1.  Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.

Authors:  W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

2.  Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia.

Authors:  B Schwartzkopff; M Mundhenke; B E Strauer
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

Review 3.  Cardiac fibrosis as a cause of diastolic dysfunction.

Authors:  Brad S Burlew; Karl T Weber
Journal:  Herz       Date:  2002-03       Impact factor: 1.443

4.  Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.

Authors:  Bodo Schwartzkopff; Michael Fassbach; Beate Pelzer; Michael Brehm; Bodo E Strauer
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

5.  Myocardial collagen type I and impaired left ventricular function under exercise in hypertrophic cardiomyopathy.

Authors:  M Mundhenke; B Schwartzkopff; P Stark; H D Schulte; B E Strauer
Journal:  Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 1.827

6.  Abnormalities of the extracellular degradation of collagen type I in essential hypertension.

Authors:  C Laviades; N Varo; J Fernández; G Mayor; M J Gil; I Monreal; J Díez
Journal:  Circulation       Date:  1998-08-11       Impact factor: 29.690

Review 7.  Hormonal regulation of cardiac fibroblast function.

Authors:  C G Brilla; B Maisch; G Zhou; K T Weber
Journal:  Eur Heart J       Date:  1995-05       Impact factor: 29.983

8.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

9.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

10.  Morphologic evidence for "small vessel disease" in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  Z Kardiol       Date:  1987
View more
  7 in total

1.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

Review 2.  Mechanisms of disease: hypertrophic cardiomyopathy.

Authors:  Norbert Frey; Mark Luedde; Hugo A Katus
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

3.  Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension.

Authors:  Oliver Dörr; Christoph Liebetrau; Helge Möllmann; Felix Mahfoud; Sebastian Ewen; Luise Gaede; Christian Troidl; Jedrzej Hoffmann; Nikolai Busch; Gerald Laux; Jens Wiebe; Timm Bauer; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2014-10-18       Impact factor: 5.460

4.  Use of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes).

Authors:  John J Ely; Micah A Bishop; Michael L Lammey; Meg M Sleeper; Jörg M Steiner; D Rick Lee
Journal:  Comp Med       Date:  2010-04       Impact factor: 0.982

5.  Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1.

Authors:  Stephen J Crocker; Ricardo F Frausto; Jason K Whitmire; Nicola Benning; Richard Milner; J Lindsay Whitton
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

Review 6.  Extracellular Matrix in Heart Disease: Focus on Circulating Collagen Type I and III Derived Peptides as Biomarkers of Myocardial Fibrosis and Their Potential in the Prognosis of Heart Failure: A Concise Review.

Authors:  Asparuh Nikolov; Nikola Popovski
Journal:  Metabolites       Date:  2022-03-28

7.  Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy.

Authors:  Chi Young Shim; Jong-Won Ha; Eui-Young Choi; Hyun-Jin Lee; Sun-Ha Moon; Jin-Mi Kim; Se-Joong Rim; Namsik Chung
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.